Objective: The Structural Biology Shared Resource (SBSR) provides UCCC researchers access to instrumentation and expertise in X-ray Crystallography and Nuclear Magnetic Resonance Spectroscopy, promoting the application of macromolecular structural studies to cancer research. Projects studied in the Core include hormone receptor and transcription regulator structures, telomere structures, tumor suppressor structures, phospholipid targeting domain structures, tumor cell surface marker structures, and chromatin assembly and disassembly structures, among others, and have resulted in >50 research publications, including many publications in high profile journals such as Cell, Nature, Science, Molecular Cell, and Nature Structural and Molecular Biology. Services &Technologies: The facilities available within the resource have expanded significantly over the last 5 years. The X-ray Core facility has 2 Raxis IV++ area detectors with a Rigaku/MSC generator and has added Rigaku/MSC robotic systems for production of crystallization screens, drop setting and plate imaging. The NMR Core facility has added a 900 MHz Varian NMR spectrometer to the existing 500 and 600 MHz spectrometers at the Anschutz Medical Campus and has added a Varian 800 MHz spectrometer at the University of Colorado Boulder campus. Consultation &Training: SBSR personnel provide sample preparation, data collection and instrument training and help investigators process data, determine structures, and prepare data for publication and presentation. Utilization: In the last year, the SBSR supported the operation of more than 30 research programs including 18 UCCC members (with ~$3.8 million of annual direct costs in grant support) from 4 different UCCC Programs and 3 UCCC consortium institutions (UCD AMC, National Jewish Health, UC Boulder). UCCC members accounted for 88% of the total usage of the facilities. Management &Finances: SBSR is UCCC managed. Approximately one-quarter of the grants serviced by the SBSR are NCI-funded;however, many of the grants funded by other NIH agencies are specifically cancer-related. Other funding has come from the American Cancer Society, Cancer League of Colorado and the National Science Foundation. In the previous year, 43% of the operating budget came from chargebacks to UCCC members who represent >90% of users. The SBSR requests $180,693 CCSG support for 40% of its operating budget. Developing facilities for structural biology research will continue, and two primary future objectives are 1) develop new projects from non-structure labs, and 2) promote closer integration with clinical research as part of target validation.

Public Health Relevance

Researchers in the Structural Biology Shared Resource determine the 3-dimensional structures of the proteins, other cellular macromolecules and their complexes that affect the development and progression of cancer, and of small molecules, potential drugs and their interactions with their therapeutic targets. Structures of molecules implicated in cancer provide clues to potential therapies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA046934-25
Application #
8567573
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-02-01
Budget End
2014-01-31
Support Year
25
Fiscal Year
2013
Total Cost
$134,699
Indirect Cost
$44,373
Name
University of Colorado Denver
Department
Type
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Scott, Aaron J; Arcaroli, John J; Bagby, Stacey M et al. (2018) Cabozantinib Exhibits Potent Antitumor Activity in Colorectal Cancer Patient-Derived Tumor Xenograft Models via Autophagy and Signaling Mechanisms. Mol Cancer Ther 17:2112-2122
New, Melissa L; White, Collin M; McGonigle, Polly et al. (2018) Prostacyclin and EMT Pathway Markers for Monitoring Response to Lung Cancer Chemoprevention. Cancer Prev Res (Phila) 11:643-654
Vartuli, Rebecca L; Zhou, Hengbo; Zhang, Lingdi et al. (2018) Eya3 promotes breast tumor-associated immune suppression via threonine phosphatase-mediated PD-L1 upregulation. J Clin Invest 128:2535-2550
Dhar, Deepanshi; Deep, Gagan; Kumar, Sushil et al. (2018) Bitter melon juice exerts its efficacy against pancreatic cancer via targeting both bulk and cancer stem cells. Mol Carcinog 57:1166-1180
da Silva, Raquel Frenedoso; Dhar, Deepanshi; Raina, Komal et al. (2018) Nintedanib inhibits growth of human prostate carcinoma cells by modulating both cell cycle and angiogenesis regulators. Sci Rep 8:9540
Majtan, Tomas; Jones Jr, Wendell; Krijt, Jakub et al. (2018) Enzyme Replacement Therapy Ameliorates Multiple Symptoms of Murine Homocystinuria. Mol Ther 26:834-844
Pei, Shanshan; Minhajuddin, Mohammad; Adane, Biniam et al. (2018) AMPK/FIS1-Mediated Mitophagy Is Required for Self-Renewal of Human AML Stem Cells. Cell Stem Cell 23:86-100.e6
Ren, Shengxiang; Rivard, Christopher J; Yu, Hui et al. (2018) A miRNA Panel Predicts Sensitivity of FGFR Inhibitor in Lung Cancer Cell Lines. Clin Lung Cancer 19:450-456
Donson, Andrew M; Amani, Vladimir; Warner, Elliot A et al. (2018) Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk Childhood Ependymoma. Mol Cancer Ther 17:1984-1994
Branchford, B R; Stalker, T J; Law, L et al. (2018) The small-molecule MERTK inhibitor UNC2025 decreases platelet activation and prevents thrombosis. J Thromb Haemost 16:352-363

Showing the most recent 10 out of 1634 publications